Bortezomib Evidence Guide
Bortezomib (Velcade) is FDA-approved for multiple myeloma and mantle cell lymphoma, with Phase 3 data across numerous trials establishing it as the foundational proteasome inhibitor in oncology. It was the first proteasome inhibitor approved and remains a backbone of myeloma treatment protocols worldwide. An extensively validated cancer therapeutic.
Our Take
Bortezomib (Velcade) is FDA-approved for multiple myeloma and mantle cell lymphoma, with Phase 3 data across numerous trials establishing it as the foundational proteasome inhibitor in oncology. It was the first proteasome inhibitor approved and remains a backbone of myeloma treatment protocols worldwide. An extensively validated cancer therapeutic.
- Best for
- Multiple myeloma (newly diagnosed and relapsed), mantle cell lymphoma, proteasome biology research
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 1.3mg/m² subcutaneous or IV twice weekly for 2 of every 3 weeks (standard cycle)
Benefits and Evidence
- Multiple Myeloma Treatment: Level A, includes human evidence - Landmark VISTA trial demonstrated superior overall survival when added to melphalan-prednisone in newly diagnosed myeloma patients ineligible for transplant.
- Mantle Cell Lymphoma: Level A, includes human evidence - Approved for relapsed mantle cell lymphoma with response rates of approximately 30-50% as monotherapy in the relapsed setting.
- Peripheral Neuropathy: Level A, includes human evidence - Dose-limiting peripheral neuropathy affects 30-40% of patients. Subcutaneous administration reduces incidence compared to intravenous.
- Bone Health Improvement: Level B, includes human evidence - Proteasome inhibition promotes osteoblast differentiation, and bortezomib has shown beneficial effects on bone metabolism in myeloma patients.
Side Effects and Warnings
- Peripheral neuropathy (sensory and motor)
- Thrombocytopenia (cyclical, platelet nadir at day 11)
- Nausea and diarrhea
- Fatigue
- Herpes zoster reactivation
- Peripheral neuropathy - dose modification required with new onset or worsening
- Thrombocytopenia - monitor platelet counts regularly
- Herpes zoster prophylaxis recommended (acyclovir)
Research Dosage References
- <strong>Subcutaneous injection</strong> - 1.3 mg/m2 - Days 1, 4, 8, 11 of 21-day cycle - Subcutaneous preferred over IV due to reduced peripheral neuropathy risk. Rotate injection sites.
- <strong>Intravenous bolus</strong> - 1.3 mg/m2 - Days 1, 4, 8, 11 of 21-day cycle - Original approved route. 3-5 second bolus injection. Higher neuropathy risk than subcutaneous.
- <strong>Subcutaneous injection</strong> - 1.3 mg/m2 - Weekly (days 1, 8, 15, 22 of 35-day cycle) - Weekly schedule used for reduced toxicity in maintenance or elderly patients.
Mechanism of Action
Bortezomib disrupts protein homeostasis through reversible proteasome inhibition: 1. 26S proteasome inhibition: Reversibly binds to the beta-5 subunit chymotrypsin-like active site, blocking protein degradation. 2. NF-kB pathway suppression: Prevents proteasomal degradation of IkB-alpha, inhibiting NF-kB-mediated survival signaling in myeloma cells. 3. Unfolded protein response: Triggers ER stress and unfolded protein response in myeloma cells, which are highly dependent on protein quality control. 4. Microenvironment disruption: Inhibits angiogenesis and myeloma cell adhesion to bone marrow stromal cells, reducing pro-survival paracrine signaling.
Legal Status
FDA-approved for multiple myeloma (2003) and mantle cell lymphoma (2006). Available by prescription only. Marketed as Velcade by Takeda. Generic versions available.
Primary Sources
- Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma (VISTA). N Engl J Med, 2008.
- Subcutaneous versus intravenous bortezomib in multiple myeloma. Lancet Oncol, 2011.
- Bortezomib in relapsed mantle cell lymphoma. J Clin Oncol, 2006.